105655-01-4

Basic information

• Product Name: 6-Bromo-3,4-dihydro-2H-benzo[1,4]oxazine hydrochloride
• Synonyms: 6-bromo-3,4-dihydro-2H-benzo[b][1,4]oxazine;6-BroMo-3,4-dihydro-2H-benzo[b][1,4]oxazine HCl;6-BROMO-3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE HYDROCHLORIDE;2H-1,4-Benzoxazine, 6-bromo-3,4-dihydro-;6-Bromo-3,4-dihydro-2H-benzo[1,4]oxazine;6-Bromo-3,4-dihydro-2H-1,4-benzoxazine
• CAS NO: 105655-01-4
• Molecular Formula: C₈H₈BrNO
• Molecular Weight: 250.52
• Mol File: 105655-01-4.mol

Chemical Properties

• Boiling Point: 296.364 °C at 760 mmHg
• Flash Point: 133.036 °C
• Appearance: /
• Density: 1.534 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.58
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 3.59±0.20(Predicted)
• CAS DataBase Reference: 6-Bromo-3,4-dihydro-2H-benzo[1,4]oxazine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-3,4-dihydro-2H-benzo[1,4]oxazine hydrochloride(105655-01-4)
• EPA Substance Registry System: 6-Bromo-3,4-dihydro-2H-benzo[1,4]oxazine hydrochloride(105655-01-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 105655-01-4(Hazardous Substances Data)

Usage

Uses

6-Bromo-3,4-dihydro-2H-1,4-benzoxazine is a reactant used for the synthesis of N-dichloroacetyl-3,4-dihydro-2H-1,4-benzoxazine derivatives.

InChI:InChI=1/C8H8BrNO/c9-6-1-2-8-7(5-6)10-3-4-11-8/h1-2,5,10H,3-4H2

Upstream product

• 24036-52-0 6-bromo-3,4-dihydro-2H-1,4-benzoxazin-3-one 
• 188947-78-6 1-(6-bromo-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)ethan-1-one 
• 698982-99-9 methyl 2-(4-bromo-2-nitrophenoxy)acetate 
• 40925-68-6 2-amino-4-bromo-phenol 
• 106-93-4 ethylene dibromide 
• 1235451-65-6 5-bromo-2-(2-bromoethoxy)benzenamine 
• 107986-49-2 N-(5-bromo-2-hydroxyphenyl)acetamide 
• 36749-01-6 2-acetamido-4-bromophenyl acetate 
• 7693-52-9 4-bromo-2-nitrophenol 
• 106-41-2 4-bromo-phenol 

Downstream Products

• 719310-31-3 tert-butyl 6-bromo-2,3-dihydrobenzo[b][1,4]oxazine-4-carboxylate 
• 1375419-04-7 2-chloro-6-fluoro-N-(4-((4-fluorophenyl)sulfonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)benzamide 
• 939759-09-8 6-iodo-3,4-dihydro-2H-benzo[b][1,4]oxazine 
• 1256256-24-2 4-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine 
• 1155264-46-2 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine 
• 1578241-63-0 methyl 2-((1r,4r)-4-(4-(4-(phenylcarbamoyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)phenyl)cyclohexyl)acetate 

Relevant articles and documents

Design, synthesis, and bioevaluation of substituted phenyl isoxazole analogues as herbicide safeners

Herbicide safeners enhance herbicide detoxification in crops without affecting target weed sensitivity. To enhance crop tolerance to the toxicity-related stress caused by the herbicide acetochlor (ACT), a new class of substituted phenyl isoxazole derivatives was designed by an intermediate derivatization method as herbicide safeners. Microwave-assisted synthesis was used to prepare the phenyl isoxazole analogues, and all of the structures were confirmed via IR, 1H NMR, 13C NMR, and HRMS. Compound I-1 was further characterized by X-ray diffraction analysis. Bioassay results showed that most of the obtained compounds provided varying degrees of safening against ACT-induced injury by increasing the corn growth recovery, glutathione content, and glutathione S-transferase activity. In particular, compound I-20 showed excellent safener activity against ACT toxicity, comparable to that of the commercial safener benoxacor. Gaussian calculations have been performed and the results indicated that the nucleophilic ability of compound I-20 is higher than that of benoxacor, thus the activity is higher than that of benoxacor. These findings demonstrate that phenyl isoxazole derivatives possess great potential for protective management in cornfields.

Simple and efficient synthesis of novel N -dichloroacetyl-3,4-dihydro-2 H -1,4-benzoxazines

An easy synthetic route to N -dichloroacetyl- 3,4-dihydro-2 H -1,4-benzoxazine derivatives 3 involves cyclization of 2-aminophenols 1 with 1,2-dibromoethane and subsequent acylation of the resultant 3,4-dihydro- 2 H -1,4-benzoxazine derivatives 2 with dichloroacetyl chloride. All compounds were characterized by IR, 1 H NMR, 13 C NMR, ESI-MS and elemental analysis. The structure of 3a was determined by X-ray crystallographic analysis.

Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold

Receptor-interacting protein kinase 2 (RIPK2) is a key mediator of nucleotide-binding oligomerization domain (NOD) cell signaling that has been implicated in various chronic inflammatory conditions. A new class of RIPK2 kinase/NOD signaling inhibitors bas

Synthesis, docking, 3-D-qsar, and biological assays of novel indole derivatives targeting serotonin transporter, dopamine D2 receptor, and mao-a enzyme: In the pursuit for potential multitarget directed ligands

A series of 27 compounds of general structure 2,3-dihydro-benzo[1,4]oxazin-4-yl)-2-{4-[3-(1H-3indolyl)-propyl]-1-piperazinyl}-ethanamides, Series I: 7(a-o) and (2-{4-[3-(1H-3-indolyl) -propyl]-1-piperazinyl}-acetylamine)-N-(2-morfolin-4-yl-ethyl)-fluorinated benzamides Series II: 13(a-l) were synthesized and evaluated as novel multitarget ligands towards dopamine D2 receptor, serotonin transporter (SERT), and monoamine oxidase-A (MAO-A) directed to the management of major depressive disorder (MDD). All the assayed compounds showed affinity for SERT in the nanomolar range, with five of them displaying Ki values from 5 to 10 nM. Compounds 7k, Ki = 5.63 ± 0.82 nM, and 13c, Ki = 6.85 ± 0.19 nM, showed the highest potencies. The affinities for D2 ranged from micro to nanomolar, while MAO-A inhibition was more discrete. Nevertheless, compounds 7m and 7n showed affinities for the D2 receptor in the nanomolar range (7n: Ki = 307 ± 6 nM and 7m: Ki = 593 ± 62 nM). Compound 7n was the only derivative displaying comparable affinities for SERT and D2 receptor (D2/SERT ratio = 3.6) and could be considered as a multitarget lead for further optimization. In addition, docking studies aimed to rationalize the molecular interactions and binding modes of the designed compounds in the most relevant protein targets were carried out. Furthermore, in order to obtain information on the structure-activity relationship of the synthesized series, a 3-D-QSAR CoMFA and CoMSIA study was conducted and validated internally and externally (q2 = 0.625, 0.523 for CoMFA and CoMSIA and r2ncv = 0.967, 0.959 for CoMFA and CoMSIA, respectively).

COMPOSITIONS FOR USE IN METHODS OF INHIBITING PROTEIN KINASES

Identified compounds demonstrate protein kinase inhibitory activity and inhibition of dependent cell signaling pathways, such as NOD2 cell signaling. More specifically, the compounds are demonstrated to inhibit receptor interacting kinase 2 (RIPK2) and/or Activin- like kinase 2 (ALK2). Compounds that are either dual RIPK2/ALK2 inhibitors or that preferentially inhibit RIPK2 or ALK2 could provide therapeutic benefit.

GLUTATHIONE-DETECTING FLUORESCENT PROBE

[Problem] To provide the following: a novel fluorescent probe for detecting a compound, such as glutathione, that contains a —SH group; a detection method using said fluorescent probe; and a detection kit containing said probe. [Solution] A fluorescent pr

N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease

The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting RORγ activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroqu

Burton's tyrosine kinase inhibitor

The invention provides a Burton's tyrosine kinase inhibitor. Particularly, a compound capable of serving as the Btk inhibitor is obtained through a wide and thorough research. It is shown through experimental results that the compound has a good inhibitin

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

MK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.